Author:
Shuen Ng Wei,Weihan Hou,Jerry Choo Jun An
Publisher
Springer Nature Singapore
Reference17 articles.
1. Bauersachs, R., Khorana, A. A., Lee, A. Y., & Soff, G. (2020). Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. Research and Practice in Thrombosis and Haemostasis, 4(4), 532–549.
2. Ding, S., Wang, L., Xie, L., Zhou, S., Chen, J., Zhao, Y., & Shao, F. (2020). Bioequivalence study of 2 formulations of rivaroxaban, a narrow-therapeutic-index drug, in healthy chinese subjects under fasting and fed conditions. Clinical Pharmacology in Drug Development, 9(3), 346–352.
3. Guengerich, F. P. (2010). Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metabolism and Pharmacokinetics, 1010210090–1010210090.
4. Irving, R. M., & Elfarra, A. A. (2012). Role of reactive metabolites in the circulation in extrahepatic toxicity. Expert Opinion on Drug Metabolism & Toxicology, 8(9), 1157–1172.
5. Julia, S., & James, U. (2017). Direct oral anticoagulants: A quick guide. European Cardiology Review, 12(1), 40.